216 related articles for article (PubMed ID: 12542120)
1. Plasma fibronectin level and its relationships with lipids, lipoproteins and C-reactive protein in patients with dyslipidaemia during lipid-lowering therapy.
Orem C; Orem A; Calapoğlu M; Baykan M; Uydu HA; Erdöl C
Acta Cardiol; 2002 Dec; 57(6):421-5. PubMed ID: 12542120
[TBL] [Abstract][Full Text] [Related]
2. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
3. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
Navarro JF; Mora C; Muros M; García-Idoate G
Nephron Clin Pract; 2003; 95(4):c128-35. PubMed ID: 14694274
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
5. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
Ridker PM; Morrow DA; Rose LM; Rifai N; Cannon CP; Braunwald E
J Am Coll Cardiol; 2005 May; 45(10):1644-8. PubMed ID: 15893181
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL.
van den Akker JM; Bredie SJ; Diepenveen SH; van Tits LJ; Stalenhoef AF; van Leusen R
J Nephrol; 2003; 16(2):238-44. PubMed ID: 12768071
[TBL] [Abstract][Full Text] [Related]
7. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
Keleş T; Akar Bayram N; Kayhan T; Canbay A; Sahin D; Durmaz T; Ozdemir O; Aydoğdu S; Diker E
Anadolu Kardiyol Derg; 2008 Dec; 8(6):407-12. PubMed ID: 19103535
[TBL] [Abstract][Full Text] [Related]
8. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
[TBL] [Abstract][Full Text] [Related]
9. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization.
Kadoglou NP; Sailer N; Moumtzouoglou A; Kapelouzou A; Gerasimidis T; Liapis CD
J Vasc Surg; 2010 Jan; 51(1):114-21. PubMed ID: 19837545
[TBL] [Abstract][Full Text] [Related]
10. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.
Kurogi K; Sugiyama S; Sakamoto K; Tayama S; Nakamura S; Biwa T; Matsui K; Ogawa H;
J Cardiol; 2013 Aug; 62(2):87-94. PubMed ID: 23672789
[TBL] [Abstract][Full Text] [Related]
11. Correlates of serum lipids and lipoproteins in Congolese patients with arterial hypertension.
Lepira FB; M'Buyamba-Kabangu JR; Kayembe KP; Nseka MN
Cardiovasc J S Afr; 2005; 16(5):249-55. PubMed ID: 16307156
[TBL] [Abstract][Full Text] [Related]
12. Plasma fibronectin level and its association with coronary artery disease and carotid intima-media thickness.
Orem C; Durmuş I; Kilinç K; Baykan M; Gökçe M; Orem A; Topbaş M
Coron Artery Dis; 2003 May; 14(3):219-24. PubMed ID: 12702925
[TBL] [Abstract][Full Text] [Related]
13. The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status.
Orem C; Orem A; Uydu HA; Celik S; Erdöl C; Kural BV
Coron Artery Dis; 2002 Feb; 13(1):65-71. PubMed ID: 11917201
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.
Hovingh GK; Kastelein JJ; van Deventer SJ; Round P; Ford J; Saleheen D; Rader DJ; Brewer HB; Barter PJ
Lancet; 2015 Aug; 386(9992):452-60. PubMed ID: 26047975
[TBL] [Abstract][Full Text] [Related]
15. Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial.
Schoenhagen P; Tuzcu EM; Apperson-Hansen C; Wang C; Wolski K; Lin S; Sipahi I; Nicholls SJ; Magyar WA; Loyd A; Churchill T; Crowe T; Nissen SE
Circulation; 2006 Jun; 113(24):2826-34. PubMed ID: 16769916
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.
Sever PS; Poulter NR; Chang CL; Thom SA; Hughes AD; Welsh P; Sattar N;
J Am Coll Cardiol; 2013 Aug; 62(8):717-29. PubMed ID: 23948514
[TBL] [Abstract][Full Text] [Related]
17. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
[TBL] [Abstract][Full Text] [Related]
18. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
19. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
Macin SM; Perna ER; Farías EF; Franciosi V; Cialzeta JR; Brizuela M; Medina F; Tajer C; Doval H; Badaracco R
Am Heart J; 2005 Mar; 149(3):451-7. PubMed ID: 15864233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]